Member Info for LiveLongnProsper

Section 3.1 updated for 'Affimer' (previously 'antibodies').
Has the lack of attention to detail (again) cost us another 2 months?
Oh well, does look like 'stars aligning' though, at last.
GLA

Tallin want CAD$70m by 15/11/21 or will move for bankruptcy.
Do COPL want to buy a) the company, or b) BF assets?
Seems more likely b), though possible tax advantage (as per @dougb189) noted.
If a), can COPL then repay the $70m? Would the Cuda shareholders actually agree to a nominal price anyway (as this is really all about the debt)? Might force insolvency anyway (maybe just for the hell of it)?
If b), can Cuda repay the $70m debt with proceeds of the asset sale?
Otherwise, if the price offered for the assets is less, are the lenders prepared to take a loss?
Are there any other prospective buyers for either the company (Cuda) or the assets? And if so are they likely to offer more?
Note Atomic PipeCo own the pipeline infrastructure for BF, so any other buyer will have to deal with COPL.
Time for a deal?
In the immortal words of ‘Crapgame’ “Then make a deal”, says ‘Big Joe’ “what kind of deal?”, retorts ‘Crapgame’ “a deal deal, business is business, right?”
We are in America, ‘business is business, right?
GLA

The relationship with POINT Biopharma could potentially be quite a ‘big deal’. It all seems to go back to Tufts and Professor William Bachovchin and Bach Biosciences …
Affimer licence agreement with Avacta in 2018 …
https://avacta.com/major-therapeutics-co-development-partnership/
Then can-SEEK for POINT in 2020 …
https://www.globenewswire.com/news-release/2020/11/10/2123598/0/en/POINT-Biopharma-and-Bach-Biosciences-announce-licensing-and-partnership-for-canSEEK-pan-cancer-targeting-technology.html
canSEEK™ is tumour targeting technology, but so is pre|CISION™.
Also discussed on Twit by @BigBiteNow earlier this year …
https://twitter.com/BigBiteNow/status/1347093736451416065
Does anyone know what the difference is between canSEEK™ and pre|CISION™?
GLA

https://finance.yahoo.com/quote/CUDA.V/
Not great for Cuda shareholders. Trading resumed with sell-off and 55% drop. Ouch!
GLA

'Hustle COPL? Why? Remember that Atomic, via Pipeco (100% owned), owns the gas pipeline infrastructure for Barron Flats.
If there were to be any competition then they will need to deal with us.
GLA

This would probably have been (could still be?) a better solution ...
https://www.lse.co.uk/rns/AVCT/update-on-affimer174-therapy-for-covid-19-infection-owdxwp4jx4rd0jx.html
Need to get Affimers through human body trials.
GLA

Just seen this posted on Twit and LSE SNG board …
https://www.dailymail.co.uk/news/article-10158061/Top-scientist-quits-SAGE-Britains-concerning-Covid-infection-rates.html
“He has called for more mask wearing, continued testing and more ventilation.”
SAGE not being listened to by this govt, no surprise there then.
GLA

@MDxExpert, great find and thanks for posting. Perhaps worth restating the very last bit again …
“Apart from the strong performance data, this new COVID-19 antigen test is an important addition to available tests because the results can be read in minutes, right off the testing card so that the patient gets the information in almost realtime. Due to its simpler design and real usability in terms of clinical performance within the cohort tested, this new antigen test could mark an important advancement in the global fight against the pandemic.”

Looks good for HUA and international sales. Come on Medusa19, the time is right …
GLA

Not quite the same thing I know, but an example of the ‘space’ pre|CISION is playing in …
https://www.europeanpharmaceuticalreview.com/news/164503/imfinzi-improves-overall-survival-in-biliary-tract-cancer-btc-patients/
Look at the scale of the trial – 145 centres in 17 countries. Note the following ...
“Imfinzi is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiation therapy and is the global standard of care in …”.

Now remember we have pre|CISION PD-1 inhibitor in the pipeline.
What if pre|CISION turned out to better in turns of overall patient outcomes than this (or other ‘big pharma’ products)? Or even just looked like it might. Are ‘they’ the competition, or are we?
Just saying.
GLA

https://twitter.com/TheEthicalTout/status/1452675827418664969
Worth a read to remind us LSE folks what we have invested in (well, most of us).
GLA

@Energyshares, would make sense, clarity (albeit speculation) appreciated.
GLA

So from …
http://www.jiabisen.com/
we get the …
Jinwofu test …
Spec – 100%, sens – 96.14% claimed, chromatographic immunoassay to detect the nuclcocapsid [sic] protein antigen
http://www.jwfbio.com/en/
and the Wisetest …
Spec – 100%, Sens – 91.8% claimed, nanocarbon assay for the qualitative detection of N antigen in Saliva sample ..
http://www.jxwisetest.com/
But …
https://cn.linkedin.com/company/jxwisetest?trk=similar-pages
Jiaxing WiseTest Bio-Tech Co., Ltd. is a wholly-owned subsidiary of VALTE International Inc. located in San Francisco Bay Area, California, USA …

All this from the Medusa19 phone number, so can someone tell me what it means to us? Are m19 collaborating with jiabisen to dell AffiDx?
Been following too many threads and got confused.
Thanks and GLA

There we go ...
https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/
GLA

70,000 today.
GLA

Yep, 'veggie'.
Peace and long life to LTH's.

Therapeutics pipeline page.
https://avacta.com/therapeutics/pipeline/
Not sure what's changed?
GLA

Been practising, think I’ve got it now?
Ready for next week, but expect the ‘experts’ will beat me to it.
GLA

1, 2, 3
1, 2, 3 ...

Testing, testing ...

https://www.walesonline.co.uk/news/uk-news/matt-han****s-whatsapp-emails-investigated-21632084
Bethell as well.
GLA